Physician profile
Mcfrances George
NPI 1669926663
$767.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $196.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $241.45 | 2021-2022 | |
| Lilly USA, LLC | $177.48 | 2021-2022 | |
| Antares Pharma, INC. | $80.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.69 | 2021-2022 | |
| Eisai INC. | $49.53 | 2021 | |
| Virtus Pharmaceuticals LLC | $24.59 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.38 | 2021 | |
| Amgen INC. | $18.50 | 2021 | |
| Hikma Pharmaceuticals USA | $18.25 | 2021 | |
| Glaxosmithkline, LLC. | $17.62 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.63 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.70 | 2021 | |
| Pfizer INC. | $11.32 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mcfrances George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.